Condition: Breast Cancer · Sponsor: Odonate Therapeutics, Inc.
CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. The primary objective of the study is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on progression-free survival (PFS) as assessed by the Independent Radiologic Review Committee (IRC). 685 patients were enrolled.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Ironwood Cancer and Research Centers | Chandler, Arizona, United States | — |
| Cancer Treatment Centers of America - Western Regional Medical Center | Goodyear, Arizona, United States | — |
| Arizona Oncology Associates, P.C. - HOPE | Tucson, Arizona, United States | — |
| Genesis Cancer Center | Hot Springs, Arkansas, United States | — |
| Carti Cancer Center | Little Rock, Arkansas, United States | — |
| Pacific Cancer Medical Center | Anaheim, California, United States | — |
| CBCC Global Research, Inc. | Bakersfield, California, United States | — |
| Compassionate Care Research Group | Fountain Valley, California, United States | — |
| California Cancer Associates for Research and Excellence | Fresno, California, United States | — |
| St. Joseph Heritage Healthcare | Fullerton, California, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| Cancer Care - Torrance Memorial Physician Network | Redondo Beach, California, United States | — |
+ 195 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03326674